Success Metrics

Clinical Success Rate

50.0%

Based on 2 completed trials

Completion Rate

50%(2/4)

Active Trials

0(0%)

Results Posted

150%(3 trials)

Terminated

2(40%)

Phase Distribution

Ph phase_1

20%

Ph phase_2

80%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

1(20.0%)

Phase 2Efficacy & side effects

4(80.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

40.0%

2 of 5 finished

Non-Completion Rate

60.0%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Terminated(3)

Detailed Status

Completed2

Terminated2

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

50.0%

Most Advanced

Phase 2

Trials by Phase

Phase 11 (20.0%)

Phase 24 (80.0%)

Trials by Status

completed240%

withdrawn120%

terminated240%

Recent Activity

0 active trials

Showing 5 of 5

terminatedphase_2

A Study to Investigate the Effects of RIST4721 on the Inflammatory Response in Healthy Male Subjects Using a Blister Model

NCT04105959

Clinical Trials (5)

Showing 5 of 5 trials

NCT05194839Phase 2

A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)

Terminated

NCT05348681Phase 2

A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS)

Terminated

NCT05448391Phase 2

A Study to Evaluate RIST4721 in Familial Mediterranean Fever (FMF)

Withdrawn

NCT03988335Phase 2

A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)

Completed

NCT04105959Phase 1

A Study to Investigate the Effects of RIST4721 on the Inflammatory Response in Healthy Male Subjects Using a Blister Model

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5